The high expression of the FGFR1 and 4 in ACCs is a promising first indication that FGFR inhibitors like ponatinib (pan-FGFR, PDGFR, SRC, RET, KIT and FLT1 inhibitor) (24), lenvatinib (VEGFR, pan-FGFR, PDGFRα, KIT and RET inhibitor) (23), rogaratinib (selective FGFR 4 inhibitor) (65) or others may have better therapeutic efficacy than the other RTK inhibitors that have been tested until now for the treatment of ACC. This evidence concerns the gene SRC and adrenal cortex carcinoma.